Business Model & Revenue
INNOVATE operates as a diversified holding company with three segments, though Infrastructure dominates revenue and earnings. The company employs approximately 3,700 people across its subsidiaries.
Infrastructure (98% of Q2 revenue): DBM Global is a fully integrated structural steel construction services platform. Its portfolio includes Schuff Steel (the largest structural steel fabricator in the US), Banker Steel, GrayWolf Integrated Construction, DBM Vircon (construction modeling and detailing), and Milco National Constructors. DBMG fabricates and erects structural steel for data centers, healthcare facilities, semiconductor plants, and advanced manufacturing — end markets driving the $2.7B adjusted backlog. Revenue is project-based with milestone billing; gross margins typically range 17-19%.
Life Sciences (<1% of revenue): Pansend Life Sciences houses two subsidiaries. MediBeacon develops the TGFR System — a transdermal kidney function monitoring device that received CE Mark under MDR and is in targeted commercial launch at 100+ healthcare institutions. R2 Technologies sells automated cold storage systems (Glacial fx) for vaccines and biologics, with approximately 110 systems in backlog globally.
Spectrum (1% of revenue): HC2 Broadcasting operates television stations and networks. This segment is being divested — INNOVATE agreed to sell 75% to CONX CORP, retaining 25%, pending FCC and regulatory approvals. The $105M refinancing closed in Q2 2026.
Financial Highlights
Q2 2026 vs Q2 2025 Comparison
| Metric | Q2 2026 | Q2 2025 | YoY Change |
|---|---|---|---|
| Revenue | $421.6M | $242.0M | +74.2% |
| Gross Profit | $79.5M | $45.6M | +74.3% |
| Gross Margin | 18.9% | 18.8% | +10 bps |
| Net Income (to common) | $10.4M | ($22.0M) | Swing to profit |
| Diluted EPS | $0.71 | ($1.67) | +$2.38 |
| Adjusted EBITDA | $46.3M | $15.7M | +194.9% |
Quarterly Progression
| Quarter | Revenue | Net Income/(Loss) | Diluted EPS | Gross Margin |
|---|---|---|---|---|
| Q4 2025 | $382.7M | ($7.8M) | ($0.58) | 17.0% |
| Q1 2026 | $364.8M | ($17.2M) | ($1.25) | 17.0% |
| Q2 2026 | $421.6M | $10.4M | $0.71 | 18.9% |
Balance Sheet (June 30, 2026)
| Item | Amount |
|---|---|
| Cash & Equivalents | $87.8M |
| Total Debt (current + long-term) | $616.0M |
| Total Assets | $1,006.7M |
| Stockholders' Deficit | ($228.6M) |
| Shares Outstanding | 13.6M |
| Float | 5.4M |
Segment Revenue (Q2 2026): Infrastructure $414.0M (+77.6%) | Life Sciences $2.2M (-31.3%) | Spectrum $5.4M (-5.3%)
H1 2026 Totals: Revenue $786.4M (+52.3%) | Adjusted EBITDA $66.0M (+188.2%) | Net Loss ($6.8M) vs ($46.8M)
No formal FY2026 guidance issued.
Competitive Landscape
DBM Global competes in the fragmented structural steel fabrication and construction market. The company differentiates through its national footprint of branded subsidiaries and integrated design-build capabilities.
Key Competitors:
- Nucor (NUE): Nation's largest steel producer with growing fabrication footprint; deep balance sheet advantage but less project integration than DBMG
- Steel Dynamics (STLD): Major steelmaker expanding into downstream fabrication; different cost structure as integrated producer
- Cives Steel: Privately held fabricator with regional presence; competes on mid-size projects
- Hensel Phelps / Turner Construction: General contractors that self-perform some steel work; potential customers and competitors
- Regional Fabricators: Highly fragmented local market with limited capacity for mega-projects
Moats:
- Scale and Geographic Reach — Schuff Steel and Banker Steel give DBMG national coverage unmatched by regional fabricators
- Backlog of Mega-Projects — $2.7B adjusted backlog includes data center and semiconductor builds requiring specialized engineering capacity
- Integrated Services — DBM Vircon (modeling/detailing) plus fabrication plus erection creates a design-build value chain competitors lack
- End-Market Exposure — Concentrated in secular growth areas: AI data centers, chip manufacturing, healthcare infrastructure
Catalysts
-
DBMG sale process — Management confirmed a formal sales process for all or substantially all of DBMG; a successful transaction above $850M could unlock significant equity value
-
CONX/Broadcasting deal close — Pending FCC approval, the 75% Broadcasting sale simplifies the corporate structure and transfers debt to CONX
-
Q3 2026 earnings — Another quarter of DBMG execution could sustain the re-rating; H2 backlog conversion drives revenue visibility
-
MediBeacon commercialization — 100+ institutions evaluating TGFR; reimbursement milestones and potential pivotal study in 2027 for wireless sensor
-
Debt restructuring — Management stated it has made and expects further changes to debt arrangements; deleveraging reduces going-concern risk
Key Risks
- Going concern doubt — 2025 10-K explicitly flags substantial doubt about ability to continue; covenant milestones on 2027 senior notes force asset sales
- Complex capital structure — $616M total debt against $229M stockholders' deficit; non-controlling interests and preferred stock complicate equity claims
- Asset sale execution risk — DBMG sale process may face valuation gaps, tax leakage, or creditor objections; distressed sale scenarios could impair equity entirely
- Extremely thin float — only 5.4M shares float creates violent price swings; limited institutional ownership and liquidity
- DBMG concentration — 98% of revenue from one segment; loss of key projects or steel cost inflation could rapidly deteriorate results
Our Thesis
INNOVATE is a misunderstood holding company trading at a fraction of its primary subsidiary's standalone value. DBM Global — a portfolio of structural steel fabricators including Schuff Steel, Banker Steel, and GrayWolf — delivered $71.7M in H1 2026 Adjusted EBITDA against a record $2.7B adjusted backlog. That backlog provides multi-year revenue visibility into the secular data center and advanced manufacturing build-out. Meanwhile, INNOVATE is dismantling its conglomerate structure: the Broadcasting segment is being sold to CONX CORP (pending FCC approval), and management has confirmed a formal sales process for DBMG itself. Life Sciences subsidiary MediBeacon is commercializing its TGFR kidney function monitoring system at 100+ healthcare institutions with CE Mark approval.
Valuation is compelling on any normalized basis. At $10.99, the stock trades at 5.2x annualized H1 EBITDA and 0.1x trailing revenue — absurdly cheap if DBMG's backlog converts. Our $16 price target applies 6.5x to FY2026E consolidated Adjusted EBITDA of $130M ($845M EV), less $528M net debt, discounted 43% for going-concern risk, debt service burden, and execution uncertainty on asset sales. The thin 5.4M share float amplifies both upside and downside. A successful DBMG sale above $850M could deliver $20+ per share; a distressed sale below $600M could wipe out equity entirely.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.